AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
36.43
-0.15 (-0.41%)
Nov 3, 2025, 10:10 AM EST - Market open
AnaptysBio Employees
AnaptysBio had 136 employees as of December 31, 2024. The number of employees increased by 19 or 16.24% compared to the previous year.
Employees
136
Change (1Y)
19
Growth (1Y)
16.24%
Revenue / Employee
$905,618
Profits / Employee
-$974,956
Market Cap
1.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136 | 19 | 16.24% |
| Dec 31, 2023 | 117 | 21 | 21.88% |
| Dec 31, 2022 | 96 | -6 | -5.88% |
| Dec 31, 2021 | 102 | 8 | 8.51% |
| Dec 31, 2020 | 94 | 5 | 5.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANAB News
- 5 days ago - Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation - GlobeNewsWire
- 19 days ago - AnaptysBio, Inc. - Special Call - Seeking Alpha
- 21 days ago - Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 - GlobeNewsWire
- 4 weeks ago - AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Benzinga
- 4 weeks ago - Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 - GlobeNewsWire
- 4 weeks ago - Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 - GlobeNewsWire
- 2 months ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire
- 3 months ago - Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire